Lilly acquires 4E Therapeutics to advance non-opioid chronic pain treatment

Innoviva Specialty Therapeutics signs licensing agreement with Dr. Reddy's for XACDURO international expansion

Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026

Kalohexis presents dual MC3R/MC4R activation data at ENDO 2026

Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease

Lonza and Antharis Therapeutics enter target-specific licence agreement

Halia Therapeutics' ofirnoflast granted FDA Fast Track designation for lower-risk myelodysplastic syndromes

Inhibrx's ozekibart BLA accepted by FDA for chondrosarcoma treatment

Sensei Biotherapeutics changes name to Faeth Therapeutics

Bayer receives FDA approval for AMBELVIST MRI contrast agent

AstraZeneca secures US approval for Truqap combination in PTEN‑deficient prostate cancer

Acousia Therapeutics reports positive top-line efficacy results for ACOU085 in cisplatin-induced ototoxicity

Menarini reports Phase 3 data for selinexor plus ruxolitinib in myelofibrosis

Simcere Pharmaceutical and Stanford Medicine agree research collaboration in idiopathic pulmonary fibrosis

Gilead Sciences mobilises remdesivir donation to support Ebola response in Uganda